During transit through the epididymis, spermatozoa are normally kept immotile and do not attain the ability to become motile until they reach the caudal epididymis. This study was undertaken to determine whether endocannabinoids play a role in the epididymis and in particular in suppressing the ability of spermatozoa to become motile. We show that the levels of the endocannabinoid 2-arachidonoylglycerol (2-AG) are high in mouse spermatozoa isolated from the caput (head) of the epididymis, where these cells do not move (or possess sluggish and irregular motility) and decrease dramatically in spermatozoa isolated from the cauda
INTRODUCTION
Endocannabinoids are an emerging class of lipid mediators isolated from the brain [1] , peripheral tissues [2] , and reproductive fluids [3] , with biological actions [4] exerted by activating the cannabinoid type-1 and type-2 receptors CNR1 and CNR2 (also known as CB1 and CB2, respectively) [5, 6] able to bind also the Cannabis constituent D 9 -tetrahydrocannabinol (THC) [1, 7] . To date, the best characterized endocannabinoids are arachidonoylethanolamide (AEA or anandamide) and 2-arachidonoyl-glycerol (2-AG) [1, [8] [9] [10] . AEA (but not 2-AG), at concentrations higher than those required to activate CNR1, additionally acts at intracellular sites of some ion channels, including the transient receptor potential vanilloid type 1 (TRPV1) generally known to be stimulated by the pungent compound of hot chili pepper, capsaicin [11] . The effects of AEA and 2-AG on cannabinoid receptors depend on their concentration in the extracellular space, which is controlled by 1) their Ca 2þ -dependent biosynthesis occurring from membrane precursors and requiring specific enzymes (primarily, N-acylphosphatidylethanolamine [NAPE]-specific phospholipase-D [PLD] for AEA [12] and sn-1-diacylglycerol lipase [DAGL] for 2-AG) [13] ; 2) cellular release and uptake, requiring a specific but as yet unidentified transporter (endocannabinoid membrane transporter, EMT) [14] ; and 3) intracellular degradation, requiring fatty acid amide hydrolase (FAAH) for AEA and monoacylglycerol lipase (MGLL) for 2-AG [15, 16] . The endocannabinoids, their receptors, and the enzymes for their synthesis and degradation constitute the ''endocannabinoid system.'' This system has recently been characterized in spermatozoa [17] , where it influences important steps controlling their functions [18] . Endocannabinoids are present in human seminal plasma [3] and in the amphibian cloacal fluid [19] . In vitro studies showed that endocannabinoids inhibit human (ejaculated spermatozoa) and frog (cloacal spermatozoa) sperm motility [19, 20] . In frogs, this effect is dependent on endocannabinoid concentration, mediated by CNR1 (like in humans) and counteracted by spermatozoa dilution or washing [20] . These data suggest that endocannabinoids control the number of motile spermatozoa by keeping them quiescent until release in the aquatic environment (''dilution mechanism''). However, it is not known yet whether in mammals, where immotile spermatozoa reach the epididymis by passive transport, the acquisition of their potential to become motile in the cauda may also be controlled by loss of endocannabinoid tone. Indeed, it is well known that immotile or sluggish spermatozoa from the caput epididymis are able to attain their full vigor and to move forward (progressive motility) in cauda only when delivered, from cauda, either in physiological solution or in the female reproductive tract [21] [22] [23] . We hypothesized that a decrease of endocannabinoid levels and/or CNR1 receptors might be responsible for potential motility acquisition (''start-up'') of spermatozoa during their travel from the caput to the cauda of the epididymis.
MATERIALS AND METHODS

Drugs Used for In Vivo and In Vitro Experiments
All drugs (Table 1 )-Anandamide (AEA; Sigma Aldrich); SR141716A (SR; Sanofy) or AM281 (Sigma Aldrich) selective CNR1 (CB1) antagonists; AM404 (Cayman Chemical) or OMDM-1 (Cayman Chemical) EMT inhibitors; Capsaicin (CPS), a TRPV1 agonist (Tocris Biosciences); Capsazepin (CPZ; Tocris Biosciences) or Iodoresiniferotoxin (IRTX; LC Laboratories) selective TRPV1 antagonists-had the purest analytical grade and were solved in ethanol or dimethyl sulfoxide (DMSO) according to the manufacturer's instructions.
Animals
Wild-type (WT) (CD1) and Cnr1 knockout (KO) mice [24] were purchased by Charles River (Charles River Laboratories) and maintained under constant temperature (228C) and lighting (12L:12LD), with food and water provided ad libitum.
All animal studies were carried out in accordance with the principles and procedures outlined in the National Institute of Health Guide for Care and Use of Laboratory Animals and approved by the Italian Ministry of Research and the Italian Ministry of Health.
Spermatozoa Collection
WT and/or Cnr1KO mice were killed by CO 2 asphyxia, and the removed epididymis were cut in caput and cauda for spermatozoa collection. Tissues (caput and cauda) were immersed separately in phosphate-buffered saline (PBS; 13.6 mM NaCl; 2.68 mM KCl; 8.08 mM Na 2 HPO 4 ; 18.4 mM KH 2 PO 4 ; 0.9 mM CaCl2; 0.5 mM MgCl2; pH 7.6) and cut into a few pieces to let spermatozoa flow out from the ducts. Then spermatozoa samples were filtered, and the eluted solution (approximately 1 3 10 6 sperm/ml, 4 ml for caput and 6 ml for cauda) was analyzed to evaluate the number of viable and motile cells.
Spermatozoa samples used for lipid extraction were sequentially centrifuged to time at 7000 3 g at 48C to accurately get rid from supernatant. Weighed pellets were immediately frozen and stored at À808C. Sampling was carried out within 5 min. Preliminarily, we have verified that sperm motility and viability are not affected by sampling procedure or by in vitro incubation.
Analysis of WT and Cnr1KO Spermatozoa
We used WT (n ¼ 8 animals) and Cnr1KO (n ¼ 6 animals) mice to analyze number of viable and motile spermatozoa from caput and cauda of epididymis. Number of viable spermatozoa was evaluated using propidium iodide and flow cytometric analysis (FACS-Calibur Flow Cytometer). Number of motile spermatozoa was evaluated by two observers under a light microscope using hemocytometer (Burker Chamber). This procedure was validated using doubleblind test [25, 26] .
In WT control animals, immotile sperm and sluggish, irregular, as well as circular (non progressive) motion was detected in caput, while vigorous progressive motility was detected in cauda spermatozoa. Data were plotted as the percentage of motile/live spermatozoa.
Western Blot Analysis
Spermatozoa were collected from caput and cauda of epididymis as described previously. The packed cells were subjected to lyses in tripledetergent buffer (PBS pH 7.4 containing 0.02% sodium azide, 0.1% SDS, 1% Nonidet P-40, 0.5% sodium deoxycholate, 4 lg/ml of leupeptin, aprotinin, pepstatin A, chymostatin, and 5 lg/ml of TPCK) and then submitted three times to sonication for 5 min, each time at 25 mW. Proteins were separated using 10% SDS-polyacrylamide gel electrophoresis and transferred to nitrocellulose filter (GHealth Care) at 280 mA for 2.5 h at 48C in order to evaluate CNR1 immunoreactivity. Filters were treated for 3 h to prevent nonspecific binding with blocking solution (5% nonfat powdered milk, 0.25% Tween-20 in Trisbuffered saline [TBS] , pH 7.6) and then incubated with the primary antibody (anti-CNR1 Ab diluted 1:1000) in PBS 3% nonfat powdered milk solution overnight at 48C on an orbital shaker. We used a polyclonal antibody directed against N-terminus domain (first 77 residues) of rat CNR1 antigen. Specificity of these antibodies has been investigated extensively in several species [19, 24, [27] [28] [29] [30] and was confirmed in the present experiments using the antibody previously preabsorbed for 18 h at 48C on orbital shaker with a large excess (2 lg) of the corresponding antigen (peptide). Filters were washed in TBS-0.25% Tween20, incubated with 1:1000 horseradish peroxidase-conjugated IgG (DAKO) in TBS-1% normal swine serum (NSS; DAKO), and then washed three times in TBS-0.25% Tween20. The immune complexes were detected using the ECL-Western blotting detection system (GHealth Care) following the manufacturer's instructions. The membranes, stripped at 608C for 30 min in stripping buffer (100 mM 2-mercaptoetanol, 2% SDS, and 62.5 mM Tris-HCl, pH 7.6), were reprobed with MAPK1 (housekeeping gene) antibody (sc-154; Santa Cruz Biotechnology) to quantify protein content.
In Vivo Treatments
WT mice were treated on alternate days with intraperitoneal (i.p.) injections of vehicle (diluted ethanol or DMSO according to the drug producer's indication), AM281 (1 mg/kg), SR (1 mg/kg), AM404 (10 mg/kg), or OMDM-1 (1 mg/kg). The treatment lasted 7 d (the period needed to move from caput to cauda), and at the end of this period, spermatozoa from caput and cauda of epididymis were separately collected, and the number of motile and viable cells was evaluated as described previously.
In Vitro Treatments of Spermatozoa
Spermatozoa separately collected from caput and cauda of epididymis were washed to get rid of epididymal endocannabinoids and treated with vehicle (0.05% ethanol or 0.005% DMSO according to relative drug concentrations used for each experiment), AEA (0.1 lM, 1 lM, 10 lM), SR141716A (1 lM, 10 lM), AM281 (10 lM), CPS (1 lM), CPZ (10 lM), or IRTX (0.5 lM). Each treatment lasted 15 min and was carried out at room temperature. Afterward, the number of motile and viable cells was evaluated as described previously. Drugs were given alone or in combination as indicated in the figures. Homogenates were centrifuged at 13 000 3 g for 16 min (48C), and the aqueous phase plus debris were collected and extracted four times with 1 volume of chloroform. The lipid-containing organic phases were dried down and prepurified by open bed chromatography on silica columns eluted with increasing concentrations of methanol in chloroform. Fractions for AEA and 2-AG measurement were obtained by eluting the columns with 9:1 (by volume) chloroform/methanol and then directly analyzed by liquid chromatographyatmospheric pressure chemical ionization-mass spectrometry (LC-APCI-MS). LC-APCI-MS analyses were carried out in the selected ion monitoring mode as described in Di Marzo et al. [31] , using m/z values of 356 and 348 (molecular ions þ1 for deuterated and undeuterated AEA) and 384.35 and 379.35 (molecular ions þ1 for deuterated and undeuterated 2-AG). AEA and 2-AG levels were therefore calculated on the basis of their area ratios with the internal deuterated standard signal areas, their amounts in pmol normalized per gram of cells or tissue.
Lipid Extraction and Endocannabinoid Measurement
DAG Lipase Enzymatic Assay
Membrane fractions obtained by differential centrifugation as described in Bisogno et al. [13] were incubated in the presence of test compounds with sn-1-[
14 C]-oleoyl-2-arachidonoylglycerol in 50 mM Tris-HCl, pH 7, for 20 min at 378C, synthesized in our laboratory as previously described [1] . After the 
MAG Lipase Enzymatic Assay
Cytosolic fraction obtained by differential centrifugation as described in Bisogno et al. [13] were incubated in the presence of test compounds with 2-[ 3 H]-arachidonoylglycerol, synthesized in our laboratory as previously described [13] in 50 mM Tris-HCl, pH 7, for 20 min at 378C. After the incubation, lipids were extracted with 2 volumes of CHCl 3 /MeOH 2:1 (by volume). The organic phases containing lipids were fractionated by TLC on silica on polypropylene plates using CHCl 3 /MeOH/NH4OH (85:15:1 by volume) as the eluting system. The band corresponding to [ 
Quantitative Real-Time PCR Analysis
Caput or cauda of the epididymis was homogenized in 1 ml of Trizol (Invitrogen). Total RNA was extracted according to the manufacturer's recommendations, dissolved in RNA storage solution (Ambion), UV quantified by a Bio-Photometer (Eppendorf), and stored to À808C. RNA aliquots (6 lg) were digested by RNAse-free DNAse I (Ambion deoxyribonucleic acid [DNA]-free kit) in a 20-ll final volume reaction mixture to remove contaminating genomic DNA. After DNAse digestion, concentration and purity of RNA samples were evaluated by the RNA-6000-Nano microchip assay, using a 2100 Bioanalyzer equipped with a 2100-Expert-Software (Agilent), following the manufacturer's instructions. For all samples tested, the RNA integrity number was greater than 6 (relatively to a 0-10 scale). Three micrograms of total RNA, as evaluated by the 2100 Bioanalyzer, were reverse transcribed in a 25-ll reaction mixture containing 50 mM Tris-HCl pH 8.3, 75 mM KCl, 3 mM MgCl 2 , 10 mM dithiothreitol, 1 mM deoxyribonucleotide triphosphates, 20 U of RNAse inhibitor (Invitrogen), 0.125 A 260 units of hexanucleotide mixture (Invitrogen) for random priming, and 200 U of MoMuLV Superscript III reverse transcriptase (Invitrogen). The reaction mixture was incubated in a thermocycler iCycler-iQ for a 5 min at a 558C step, followed by a rapid chilling for 2 min at 48C. The protocol was stopped at this step, and the MoMuLV reverse transcriptase was added to the samples, except for the negative controls (-RT). The incubation was resumed by two thermal steps: 10 min at 208C followed by 90 min at 508C. Finally, the reaction was terminated by heating at 958C for 10 min. Quantitative real-time PCR was performed by an iCycler-iQ in a 25-ll reaction mixture containing 13 iQ-SYBR-Green-Supermix (Bio-Rad), 20 ng of complementary DNA (cDNA; calculated on the basis of the retrotranscribed RNA), and 330 nM for each primer. The amplification profile consisted of an initial denaturation of 2 min at 948C and 40 cycles of 30 sec at 948C, annealing for 30 sec at optimum annealing temperature (TaOpt; see the following discussion), and elongation for 45 sec at 688C. Fluorescence data were collected during the elongation step. A final extension of 7 min was carried out at 728C, followed by melt-curve data analysis. Optimized primers for SYBR-Green analysis (and relative TaOpt) were designed by the Beacon-Designer software 6.0 version (Biosoft International) and were synthesized (high-performance liquid chromatography purification grade) by MWG-Biotech AG. Assays were performed in quadruplicate (maximum DCt of replicate samples less than 0.5), and a standard curve from consecutive fivefold dilutions (100-0.16 ng) of a cDNA pool representative of all samples was included for PCR efficiency determination. Relative expression analysis, correct for PCR efficiency and normalized with respect to reference gene b-actin, was performed by GENEX software (Bio-Rad) for groupwise comparison and statistical analysis.
Statistical Analysis
Student t-test or analysis of variance (ANOVA) followed by the Duncan test for multigroup comparison was performed, when appropriate, to evaluate the significance of differences for number of motile spermatozoa. Data were expressed as the mean 6 SEM from at least three or four independent experimental procedures.
ANOVA followed by the Bonferroni test was used to evaluate the significance of differences for endocannabinoid levels in spermatozoa and epididymis. Data were expressed as the mean 6 SEM from at least three or four independent assays.
Tukey and Student-Newman-Keuls tests were carried out to evaluate the significance of differences for endocannabinoid levels in spermatozoa and epididymis of animals treated with OMDM-1. Data were expressed as the mean 6 SEM from at least three or four independent assays.
RESULTS
Evaluation of CNR1 Role in Epididymal Sperm
We determined the percentage of motile spermatozoa from epididymis, caput, and cauda separately of control WT and Cnr1KO mice (Fig. 1A) . In control animals, the percentage of motile spermatozoa was significantly higher (P , 0.01) in cauda than in caput. In Cnr1KO animals, the percentage of motile spermatozoa from caput was significantly higher (P , 0.01) as compared with values of spermatozoa collected from the caput of WT mice. Furthermore, no differences were observed in the percentage values of spermatozoa collected from the cauda of WT or caput and cauda of Cnr1KO animals. Interestingly, caput spermatozoa of Cnr1KO animals were characterized by vigorous motility. 
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The percentage of motile spermatozoa was also counted in the epididymis of WT animals pharmacologically treated with selective CNR1 antagonists AM281 or SR. The administration of AM281 (Fig. 1B) (Fig. 1C) . Indeed, while SR increased the number of vigorously motile spermatozoa in the caput, it decreased their percentage in cauda, suggesting an additional effect of SR per se in our system. Interestingly, although SR is reported to be a specific CNR1 antagonist, it has also been reported to act as partial TRPV1 agonist at concentrations .1 lM [32] , and TRPV1 is expressed in spermatozoa [17] . Starting from the previously mentioned observations, we carried out a series of in vitro experiments to characterize 1) the SR effect on cauda spermatozoa and 2) the receptor(s) regulating spermatozoa motility and their activity in caput and cauda spermatozoa.
Characterization of SR Effect on Caudal Spermatozoa Motility
Spermatozoa separately collected from caput and cauda of WT animals were washed to get rid of endocannabinoids and then directly stimulated with different drugs (SR 6 IRTX; CPS 6 CPZ). Interestingly, washed spermatozoa acquired higher capability to move. Indeed, the percentage of both caput and cauda motile spermatozoa was higher ( Fig. 2A , control values) as compared with unwashed (Fig. 1A , control values) spermatozoa analyzed in in vivo experiments (P , 0.01).
SR alone did not affect the percentage of motile spermatozoa collected from caput (as expected due to the absence of inhibitory stimuli to be counteracted in vitro), but it inhibited that in those collected from the cauda (P , 0.01) (Fig. 2A) . This decrease perfectly mirrored the result obtained in the   FIG. 2 . Characterization of SR effect on cauda spermatozoa. Sperm analysis after in vitro treatment with SR alone (A) or in combination with TRPV1 antagonist, IRTX (B). Effect of the TRPV1 agonist CPS, with or without the TRPV1 antagonist CPZ, on spermatozoa motility (C). SPZ, spermatozoa.
FIG. 3. Characterization of CNR1 and
TRPV1activity in caput and cauda spermatozoa. Dose-response curves of AEA on spermatozoa collected from caput (A) and cauda (B) epididymis (in vitro treatment); 1 lM AEA was also combined with the CNR1 antagonist AM281. Evaluation of CNR1 and MAPK1 (housekeeping gene) expression in caput and cauda spermatozoa by Western blot analysis (C). Data are means 6 SEM. SPZ, spermatozoa.
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cauda of WT mice treated with SR in vivo (Fig. 1C) , in which, however, the compound did elevate motility in the caput as observed with AM281 but suggested an additional effect of SR as TRPV1 agonist on cauda spermatozoa. With this in mind, we attempted to counteract SR effect on cauda spermatozoa using the IRTX, the most potent TRPV1 antagonist tested so far. The combined treatment restored the percentage of motile spermatozoa collected from cauda to control values, thus confirming the dual effect (CNR1 antagonist-TRPV1 agonist) of SR in our system (Fig. 2B) . Furthermore, incubation of spermatozoa collected from caput and cauda in the presence or absence of the TRPV1 agonist CPS, alone or in combination with another TRPV1 antagonist, CPZ, confirmed the existence of a TRPV1-mediated inhibitory effect on motility only in cauda spermatozoa (P , 0.01) (Fig. 2C ). In agreement with the relative potency of these two compounds as TRPV1 agonists, SR was less efficacious as compared to CPS, being the percentage of motile spermatozoa lower when CPS rather than SR was used (40.4 6 1.54% vs. 58.3 6 1.39%; P , 0.01).
Characterization of CNR1 and TRPV1 Activity in Caput and Cauda Spermatozoa
Spermatozoa separately collected from caput and cauda of WT animals were washed to get rid of endocannabinoids and stimulated with increasing AEA doses, the true ligand for both CNR1 and TRPV1 receptors. The first observation to emerge was that washed spermatozoa acquired (once again) higher capability to move although preserving their own properties. Indeed, the percentage of both caput (Fig. 3A) and cauda (Fig.  3B ) motile spermatozoa was higher as compared with unwashed sperm analyzed in in vivo experiments (P , 0.01). Worthy of note, we observed that AEA decreased the percentage of motile spermatozoa collected from the caput ( Fig. 3A ; P , 0.01) or cauda ( Fig. 3B ; P , 0.01) with the same IC 50 (0.5 lM). This effect was counteracted by the selective CNR1 antagonist AM281. Interestingly, high AEA concentration (10 lM) further decreased the percentage of motile spermatozoa collected from cauda, suggesting an additional TRPV1-mediated AEA effect only in cauda epididymis (Fig.  3B) . Furthermore, Western blot analysis revealed that CNR1 levels in caput and cauda spermatozoa did not change (Fig.  3C ).
AEA and 2-AG Measurement along the Epididymis
The levels of 2-AG, but not AEA, significantly (P , 0.01) and dramatically (;30-fold) decreased from caput to cauda spermatozoa (Fig. 4A) . 2-AG but not AEA levels also decreased (P , 0.05) in the controlateral cauda epididymal tissue used to prepare spermatozoa for endocannabinoid measurement, but to a much lower extent as compared with levels measured in spermatozoa (;1.9-fold) (Fig. 4B) .
Expression/Activity of Synthesizing and Degrading Enzymes for 2-AG along the Epididymis
We analyzed, through quantitative real-time PCR, the expression/activity of 2-AG major biosynthesizing (DAGLA) and degrading (MGLL) enzymes. We showed that the enzymatic activity of DAGLA significantly (P , 0.01) increased in cauda spermatozoa, whereas MGLL activity decreased ( Table 2) . By contrast, the expression of these enzymes in the epididymal tissue appeared to be regulated in the opposite way, with an increase (P , 0.01) of Mgll mRNA and a decrease (P , 0.01) of Dagla mRNA in the cauda ( Table  2) .
Effects of AM404 and OMDM-1 on Sperm Motility and 2-AG Levels
In control animals (Fig. 5, A and B) , the percentage of motile spermatozoa significantly (P , 0.01) increased in the cauda. When administered i.p., both AM404 and OMDM-1 (two different EMT inhibitors), while being ineffective on caput values, significantly (P , 0.01) decreased the percentage of vigorously motile spermatozoa in the cauda (Fig. 5, A and  B) .
Measurement of 2-AG, after OMDM-1 treatment (Fig. 5C ), revealed that its levels significantly (P , 0.01) increased in cauda reaching caput values. However, both caput and cauda 2-AG levels after OMDM-1 treatment were significantly lower (P , 0.05) as compared with caput control values.
DISCUSSION
The percentages of motile spermatozoa collected from the caput and cauda epididymis of WT and Cnr1KO mice [33] were assessed in order to investigate the involvement of CNR1 
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in the regulation of the potential of sperm for progressive motility. The percentage of motile spermatozoa collected from caput was higher in Cnr1KO than in WT mice. Conversely, the percentage of motile spermatozoa in the cauda of both WT and KO animals was similar. Interestingly, vigorous motility was observed in the caput of KO mice. We concluded that the absence of functional CNR1 causes a precocious acquisition of motility in spermatozoa present in the caput, which becomes comparable to that observed in the cauda. Accordingly, we found that either SR or AM281 administration, two different selective CNR1 antagonists, mimicked the Cnr1KO phenotype by increasing number of vigorously motile spermatozoa in the caput. Unexpectedly, SR decreased the percentage of motile spermatozoa in the cauda, suggesting an additional effect of SR per se in our system. We ascribed this effect to the capability of SR to activate TRPV1 at concentrations .1 lM [32, 34] . Indeed, the presence of TRPV1 in mouse spermatozoa has recently been demonstrated by Grimaldi et al. [35] . Accordingly, in vitro experiments demonstrated that SR (10 lM), as well as the prototypical TRPV1 agonist CPS (1 lM), decreased percentage of motile spermatozoa in the cauda but not in the caput being SR less efficacious as compared with CPS. Both the effects were counteracted by TRPV1 antagonists, thus strongly suggesting 1) the dual effect (CNR1 antagonist-TRPV1 agonist) of SR in our system, 2) the activation of TRPV1 in spermatozoa [35] , and 3) the existence of a TRPV1-mediated inhibitory effect on motility only in cauda spermatozoa (P , 0.01). Since spermatozoa are translationally inactive cells and protein modifications (i.e., changes in glycosylation and phosphorylation rates) are usually described during the journey through the epididymis [36] , we suggest that the observed TRPV1-mediated response is due to a protein modification specifically occurring in cauda spermatozoa. Accordingly, it is well established that phosphorylation modulates TRPV1 activity [37] . The unexpected TRPV1 effect hints that both CNR1 and TRPV1, or a shifted activity of the former versus the latter, might induce spermatozoa to acquire potential progressive motility in cauda. In order to verify the true role of both receptors, we directly stimulated caput or cauda spermatozoa with increasing AEA doses. We observed that AEA, via CNR1, decreased the percentage of motile spermatozoa collected from the caput and cauda with the same IC 50 of 0.5 lM. Furthermore, high AEA concentration (.1 lM) further decreased the percentage of motile spermatozoa collected from cauda, suggesting, as expected, a TRPV1-mediated additional AEA effect only in cauda epididymis. These results suggest that CNR1 activation inhibits either caput or cauda spermatozoa motility, while high AEA concentrations are requested to further inhibit motility of cauda spermatozoa via TRPV1. Therefore, differences in percentage of motile spermatozoa between caput and cauda are not likely to derive either from the different function of CNR1 or TRPV1 or from the combined activity of both receptors and not even from the different expression of CNR1. Indeed, Western blot analysis demonstrated that CNR1 expression levels were not different in spermatozoa from caput or cauda.
The previously described data suggest that, although either CNR1 or TRPV1 activation reduced the percentage of motile spermatozoa, changes in the activity triggered by the former rather than the latter (functionally active only in cauda spermatozoa at high AEA concentrations) might be responsible for spermatozoa start-up when passing from caput to cauda of the epididymis. We reasoned that, since CNR1 functional activity, assessed using submicromolar and cannabinoid receptor-specific concentrations of the same agonist (AEA), was identical in spermatozoa from these two parts of the epididymis, the acquisition of their potential to become motile, if due to changes in endocannabinoid tone (as suggested by experiments with Cnr1KO mice and AM281), might be caused by a decrease of endocannabinoid levels. With this in mind, and in order to determine which ligand was actually involved, we measured the levels of AEA and 2-AG in isolated caput and cauda spermatozoa. The levels of 2-AG but not AEA significantly (P , 0.01) and dramatically (;30-fold) decreased from caput to cauda spermatozoa. 2-AG but not AEA levels also decreased in the controlateral cauda epididymal tissue used to prepare spermatozoa for endocan-FIG. 5. EMT inhibitors disrupt the 2-AG gradient. Disruption of 2-AG gradient by treatment of rats with the inhibitors of endocannabinoid cellular release and reuptake, AM404 (A) or OMDM-1 (B). The treatment lasted 7 days since this is the interval necessary for caput spermatozoa to reach the cauda. For sperm collection and analysis, see Material and Methods. C) Quantitative analysis of 2-AG in caput and cauda spermatozoa of WT mice in vivo treated with OMDM-1. Spermatozoa were from mice different from those used for the experiment in Figure 3 . Data are means 6 SEM. SPZ, spermatozoa.
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nabinoid measurement but to a much lower extent as compared with levels detected in spermatozoa (;1-9-fold). Since we used whole epididymal caput and cauda tissue containing spermatozoa (technically it is very hard to achieve spermatozoa-free tissues) to measure AEA and 2-AG, it is possible that the change in endocannabinoid levels observed in the cauda epididymis was a mere reflection of the much stronger effect found in isolated spermatozoa. Therefore, our analytical findings support the hypothesis that the increased percentage of motile spermatozoa collected from the cauda is caused by decreased levels of 2-AG, resulting, in turn, in a decreased activity of CNR1. It is hard to reconcile this observation with the known protective effect exerted by endocannabinods against oxidative stress [38] . In this respect, additional protective substances may be used for cauda spermatozoa despite low 2-AG levels. Recently, Sun et al. 2009 [39] reported the compromised motility and fertilizing capacity of epididymal Faah null (Faah -/-) spermatozoa. Authors concluded that this phenotype was due to high AEA/ CNR1 activity, as the normal phenotype was recovered in double-knockout spermatozoa (Faah -/-/Cnr1 -/-). Although our results confirmed that motility of epididymal spermatozoa is responsive to AEA via both CNR1 and TRPV1, however, they indicate that 2-AG/CNR1 activity is the physiological signal regulating spermatozoa start-up in cauda epididymis. Further studies are necessary to reveal activity of all elements of the endocannabinoid system in the epididymis, possibly focusing on specific mechanisms operating in caput and cauda Faah -/-or Faah -/-/Cnr1 -/-epididymis. Finally, we wanted to investigate the possible mechanism through which the gradient of 2-AG levels in spermatozoa is generated when passing from the caput to the cauda of the epididymis. Apart from the expression/activity of its major biosynthesizing (DAGLA) and degrading (MGLL) enzymes, the levels of 2-AG acting on CNR1 are controlled by cellular release and reuptake via a still putative, albeit seemingly specific, transport mechanism that has been pharmacologically characterized in boar spermatozoa [17] . However, DAGLA and MGLL have not yet been identified in mammalian spermatozoa or in the epididymis. Here, we provided evidence for the occurrence of these enzymes in 1) spermatozoa, in which, being that these cells not translationally active, we used specific enzyme assays, and 2) the epididymis, in which, being that this tissue is strongly contaminated with transcriptionally/translationally inactive spermatozoa, we used quantitative real-time PCR (Table 2) . We showed evidence that the gradient of 2-AG levels in spermatozoa cannot be caused directly by changes in the activity/expression of DAGLA or MGLL since the enzymatic activity of DAGLA significantly increased in cauda spermatozoa, whereas MGLL activity decreased. By contrast, the expression of these enzymes in the epididymal tissue appeared to be regulated in the opposite way, with an increase of Mgll mRNA and a decrease of Dagla mRNA in the cauda. This was a puzzling result, and the only way to reconcile these findings with the observed decreased 2-AG levels in cauda spermatozoa was to speculate that this latter phenomenon is the result of a progressive gradient-driven transport of 2-AG from sperm cells to epididymal epithelial cells during the travel of spermatozoa from the caput to the cauda. This process would also explain why the levels of 2-AG in caput epididymis and spermatozoa were comparable, whereas those in cauda epididymis were significantly higher than those in cauda spermatozoa despite the fact that changes in metabolic enzymes expression/activity should have caused the opposite effect. We postulated that the ''stripping'' of 2-AG from spermatozoa by the epididymis would be 1) driven by the observed increased MGLL expression in the cauda of this tissue and by decreased 2-AG degradation and increased 2-AG biosynthesis in cauda spermatozoa and 2) facilitated by the putative specific transport mechanism in both spermatozoa and epididymal epithelial cells, a process that is known to be driven by the gradient of endocannabinoid concentrations across plasma membranes. In agreement with this hypothesis, we found that two inhibitors of endocannabinoid cellular uptake and release, AM404 and OMDM-1 [40, 41] , disrupted the increase in the number of motile spermatozoa found in the cauda. Furthermore, the effect of OMDM-1 was accompanied by a significant enhancement of the levels of 2-AG in cauda spermatozoa despite the fact that, in this set of experiments, the extent of the gradient was lower than in the first set of experiments but still very marked (3.5-fold higher levels of 2-AG in caput).
In conclusion, along the epididymis, the decrease of 2-AG levels from caput to cauda promotes sperm start-up by releasing spermatozoa from the inhibition exerted by CNR1 activation. These changes correspond to a functional 2-AG gradient that, by keeping the inhibitory activity of CNR1 high in caput and low in cauda spermatozoa, controls their potential to become motile during the travel in the epididymis. It is intriguing to observe how the endocannabinoid gradient seems to regulate both male and female reproduction since the gradient of AEA levels underlies both oviductal transport of embryos and their uterine implantation in the mouse [42] [43] [44] . Interestingly, the 2-AG gradient in mouse spermatozoa is not due to the ''dilution mechanism'' (evolutionarily selected by the external ''aquatic'' fertilization) postulated for amphibian spermatozoa [20] but seems the result of 2-AG sequestration from the epididymis driven by changes in 2-AG metabolic enzymes in this tissue that are opposite to those observed in spermatozoa. Clearly, the conclusive confirmation of this mechanism, which was suggested here by the results of biochemical, pharmacological, and analytical experiments, will require the molecular characterization of the endocannabinoid transporter and its detection in mouse epididymis. However, both mechanisms ensure the right number of motile spermatozoa by decreasing endocannabinoid activity although using, of course, different strategies. Disruption of this mechanism, if translated to humans, might explain in part those cases of male infertility that are due to the impairment of sperm motility. As a consequence, our findings might open new avenues for the pharmacological treatment of this ever-increasing medical and social problem.
